Connect with us

Psilocybin

Numinus Upgrades Psychedelics Lab to Increase Research Service Capabilities

Quick Take: The new space will be dedicated to the following services: Bioanalytical testing, Bioassay and in-vitro studies, Research & development…

Published

on

Quick Take:

The new space will be dedicated to the following services:

  • Bioanalytical testing,
  • Bioassay and in-vitro studies,
  • Research & development and formulation studies for several psychedelic compounds, including ketamine and LSD, and,
  • Small batch manufacturing.

Numinus Wellness Inc. (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to announce the expansion of its psychedelics research facility with an additional lab and application for federal licensing, as it continues to broaden its services to support industry research and production while adding new revenue streams. As previously announced in a news release dated March 9, 2021, the expanded lab is housed in an existing Numinus-leased building adjacent to the current lab.

Numinus Bioscience, the Company’s research vertical and a provider of contract services, has submitted its application to Health Canada for its second Dealer’s License, for an additional 7,500 square feet. This facility will double the size of Numinus’ research footprint and is slated for completion in Summer 2022.

The new space will be dedicated to the following services:

  • Bioanalytical testing,
  • Bioassay and in-vitro studies,
  • Research & development and formulation studies for several psychedelic compounds, including ketamine and LSD, and,
  • Small batch manufacturing.

The site design and application include a Level 7 security directive that permits expanded import, storage and distribution capabilities along with long-term stability studies for multiple products. Together, these services present significant new revenue drivers through opportunities for short-term and long-term partnerships with other industry stakeholders. Numinus already provides services to several psychedelics organizations for analytic testing, product development and ancillary services.

“As the psychedelics industry grows, supply of clinical-grade materials and access to qualified research facilities and talent are increasingly becoming bottlenecks. Numinus Bioscience addresses this need by offering services and partnership opportunities that leverage our federal licence, expertise and state-of-the-art facility,”

Sharan Sidhu, Numinus’ Science Officer and General Manager

The existing space will be dedicated to cultivating fungal starting materials such as Psilocybe mushrooms, and studying additional, currently under-researched, psychedelic botanicals. Already available and operating through its existing Health Canada licence and lab, the current site will expand its capabilities in extraction research, optimization and genomics for a variety of psychedelic materials. It will also continue to develop its verified Psilocybe tissue culture bank. These assets, along with provision of raw materials, finished dosages and regulatory support, will help industry stakeholders advance their initiatives in clinical and benchtop research.

To date, Numinus Bioscience has developed standardized analytical methods for psilocybin, psilocin, baeocystin, norbaeocystin, tryptophan, norpsilocin, aeruginascin, ketamine, LSD, MDMA and mescaline. The suite of testing services available also includes contaminant and impurity testing. Through ongoing optimization work, Numinus has also published a High Performance Liquid Chromatography (HPLC) Column Application technical note with Imtakt Corp.: “High Resolution Accurate Mass (HRAM) Analysis of Magic Mushroom Psychedelics“, highlighting both companies’ commitment to innovation and rigorous methodologies.

“With our established lab expertise and expanded service offering, we are addressing the industry’s research and supply needs while increasing our revenue streams to drive further growth. We will continue to invest in key infrastructure like our lab as we advance our integrated model in a thoughtful and sustainable manner,” “As industry leaders, we recognize it is essential to leverage our assets to support allied groups in order to achieve our mission of increasing accessibility in mental healthcare.”

Payton Nyquvest, Numinus’ Founder & CEO

About Numinus

Numinus Wellness (TSXV: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Read More

Trending